[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftIMzBY77yJMs3lol4l4-LMzSnhh5D1wv81xdAdTJVC4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":55,"rows":62},"Hospital Clinic of Barcelona",[4],316,false,40,24,2077756,6,237,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Atrial Fibrillation",12,{"name":18,"count":19},"HIV Infections",10,{"name":21,"count":22},"Cirrhosis",7,{"name":24,"count":22},"HIV Infection",{"name":26,"count":11},"Obesity",{"name":28,"count":29},"Colorectal Cancer",5,{"name":31,"count":29},"Breast Cancer",{"name":33,"count":29},"Chronic Disease",[35,40,45,50],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06619600","Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction","2025-03-31","Dapagliflozin",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05797792","CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).","2025-08-26","Intraarterial alteplase",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06760741","PREVENPANC Project: a Spanish Multicenter Study for Pancreatic Cancer Prevention","2026-11","Multigene panel",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07502781","Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants","2028-12","Cord Blood Red Blood Cells",[56,57,58,59,60,61],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[63,100,124,150,168,199,217,256,291,329,367,395,413,431,458,482,505,523,548,575,602,620,644,668,691,715,743,768,793,811,833,860,887,913,931,961,979,997,1015,1033,1051,1069,1094,1117,1135,1153,1182,1200,1223,1247,1272,1298,1323,1345,1363,1391,1409,1427,1445,1474,1492,1510,1535,1553,1576,1601,1629,1652,1675,1699,1721,1747,1773,1791,1809,1827,1851,1875,1898,1924,1942,1966,1989,2012,2037,2055,2079,2116,2158,2183,2201,2228,2258,2279,2305,2323,2347,2375,2400,2425,2443,2473,2491,2514],{"intervention":44,"totalTrials":64,"cells":65},2,{"EARLY_PHASE1":66,"PHASE1":69,"PHASE2":71,"PHASE3":73,"PHASE4":96,"NA":98},{"trials":67,"activeCount":68},[],0,{"trials":70,"activeCount":68},[],{"trials":72,"activeCount":68},[],{"trials":74,"activeCount":95,"soonestReadout":43},[75,86],{"nctId":76,"briefTitle":77,"status":78,"phases":79,"primaryCompletion":80,"completion":80,"start":81,"enrollment":82,"conditions":83,"interventions":85},"NCT03876119","Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy","COMPLETED",[58,59],"2021-05-31","2018-12-05",121,[84],"Stroke, Acute",[44],{"nctId":41,"briefTitle":42,"status":87,"phases":88,"primaryCompletion":43,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"ACTIVE_NOT_RECRUITING",[59],"2025-11-14","2023-11-18",440,[93,84],"Stroke, Acute Ischemic",[44],1,{"trials":97,"activeCount":68},[],{"trials":99,"activeCount":68},[],{"intervention":39,"totalTrials":95,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":120,"NA":122},{"trials":103,"activeCount":68},[],{"trials":105,"activeCount":68},[],{"trials":107,"activeCount":68},[],{"trials":109,"activeCount":95,"soonestReadout":38},[110],{"nctId":36,"briefTitle":37,"status":87,"phases":111,"primaryCompletion":38,"completion":38,"start":112,"enrollment":113,"conditions":114,"interventions":119},[59],"2021-05-30",54,[115,116,117,118],"ST-segment Elevation Myocardial Infarction (STEMI)","Diabetes Mellitus","Heart Failure","Myocardial Fibrosis",[39],{"trials":121,"activeCount":68},[],{"trials":123,"activeCount":68},[],{"intervention":49,"totalTrials":95,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":127,"activeCount":68},[],{"trials":129,"activeCount":68},[],{"trials":131,"activeCount":68},[],{"trials":133,"activeCount":68},[],{"trials":135,"activeCount":68},[],{"trials":137,"activeCount":95,"soonestReadout":48},[138],{"nctId":46,"briefTitle":47,"status":139,"phases":140,"primaryCompletion":48,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":148},"NOT_YET_RECRUITING",[],"2026-12","2025-01",900,[145,146,147],"Pancreatic Cancer, Adult","Hereditary Pancreatic Cancer","Familial Pancreatic Cancer",[49,149],"Generation of 3D Pancreatic Organoids",{"intervention":149,"totalTrials":95,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":162},{"trials":153,"activeCount":68},[],{"trials":155,"activeCount":68},[],{"trials":157,"activeCount":68},[],{"trials":159,"activeCount":68},[],{"trials":161,"activeCount":68},[],{"trials":163,"activeCount":95,"soonestReadout":48},[164],{"nctId":46,"briefTitle":47,"status":139,"phases":165,"primaryCompletion":48,"completion":141,"start":142,"enrollment":143,"conditions":166,"interventions":167},[],[145,146,147],[49,149],{"intervention":54,"totalTrials":95,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":180},{"trials":171,"activeCount":68},[],{"trials":173,"activeCount":68},[],{"trials":175,"activeCount":68},[],{"trials":177,"activeCount":68},[],{"trials":179,"activeCount":68},[],{"trials":181,"activeCount":95,"soonestReadout":53},[182],{"nctId":51,"briefTitle":52,"status":139,"phases":183,"primaryCompletion":53,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":197},[61],"2029-12","2027-01",176,[188,189,190,191,192,193,194,195,196],"Extremely Premature Infant","Anemia Neonatal","Blood Transfusion","Umbilical Cord Blood","Fetal Hemoglobin","Bronchopulmonary Dysplasia (BPD)","Retinopathy of Prematurity (ROP)","Death; Neonatal","Intensive Care Units, Neonatal",[54,198],"Standard Adult Donor Red Blood Cells",{"intervention":198,"totalTrials":95,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":211},{"trials":202,"activeCount":68},[],{"trials":204,"activeCount":68},[],{"trials":206,"activeCount":68},[],{"trials":208,"activeCount":68},[],{"trials":210,"activeCount":68},[],{"trials":212,"activeCount":95,"soonestReadout":53},[213],{"nctId":51,"briefTitle":52,"status":139,"phases":214,"primaryCompletion":53,"completion":184,"start":185,"enrollment":186,"conditions":215,"interventions":216},[61],[188,189,190,191,192,193,194,195,196],[54,198],{"intervention":218,"totalTrials":64,"cells":219},"terlipressin",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":241,"NA":254},{"trials":221,"activeCount":68},[],{"trials":223,"activeCount":68},[],{"trials":225,"activeCount":68},[],{"trials":227,"activeCount":68},[228],{"nctId":229,"briefTitle":230,"status":78,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":238},"NCT00628160","Terlipressin in Septic Shock in Cirrhosis",[58,59],"2012-12","2006-10",72,[236,237],"Liver Cirrhosis","Septic Shock",[239,240],"Terlipressin","alpha adrenergic drugs",{"trials":242,"activeCount":68},[243],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT00287664","Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin","SUSPENDED",[60],"2006-09","2002-02",100,[21,252],"Hepatorenal Syndrome",[218],{"trials":255,"activeCount":68},[],{"intervention":257,"totalTrials":64,"cells":258},"Tenofovir, emtricitabine, lopinavir\u002Fr",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":289},{"trials":260,"activeCount":68},[],{"trials":262,"activeCount":68},[],{"trials":264,"activeCount":68},[],{"trials":266,"activeCount":68},[],{"trials":268,"activeCount":68},[269,279],{"nctId":270,"briefTitle":271,"status":78,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":277},"NCT01533272","Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR\u002FRITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)",[60],"2014-06","2012-02",240,[24],[278,257],"Tenofovir, emtricitabine, maraviroc",{"nctId":280,"briefTitle":281,"status":78,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":275,"conditions":285,"interventions":286},"NCT01576731","Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir\u002FRitonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)",[60],"2014-07","2012-07",[24],[287,288],"Tenofovir, Emtricitabine, Lopinavir\u002Fr","Tenofovir, Emtricitabine, Raltegravir",{"trials":290,"activeCount":68},[],{"intervention":292,"totalTrials":64,"cells":293},"Sildenafil",{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":327},{"trials":295,"activeCount":68},[],{"trials":297,"activeCount":68},[],{"trials":299,"activeCount":68},[],{"trials":301,"activeCount":68},[],{"trials":303,"activeCount":68},[304,316],{"nctId":305,"briefTitle":306,"status":78,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":315},"NCT00491803","Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD)",[60],"2008-11","2009-02","2007-06",20,[313,314],"Chronic Obstructive Pulmonary Disease","Pulmonary Hypertension",[292,292],{"nctId":317,"briefTitle":318,"status":78,"phases":319,"primaryCompletion":320,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":326},"NCT01055405","Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension",[60],"2011-03","2012-01","2008-08",65,[325,314],"COPD",[292],{"trials":328,"activeCount":68},[],{"intervention":330,"totalTrials":64,"cells":331},"Iron sucrose",{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":340,"NA":365},{"trials":333,"activeCount":68},[],{"trials":335,"activeCount":68},[],{"trials":337,"activeCount":68},[],{"trials":339,"activeCount":68},[],{"trials":341,"activeCount":68},[342,353],{"nctId":343,"briefTitle":344,"status":345,"phases":346,"primaryCompletion":232,"start":347,"enrollment":348,"conditions":349,"interventions":352},"NCT01084122","Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia","UNKNOWN",[60],"2010-05",360,[350,351],"Hip Fracture","Surgical Intervention",[330],{"nctId":354,"briefTitle":355,"status":78,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":363},"NCT00660933","Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia",[60],"2007-09","2005-09",70,[361,362],"Anemia","Puerperal Disorders",[330,364],"NaCl",{"trials":366,"activeCount":68},[],{"intervention":368,"totalTrials":95,"cells":369},"flecainide",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":393},{"trials":371,"activeCount":68},[],{"trials":373,"activeCount":68},[],{"trials":375,"activeCount":68},[],{"trials":377,"activeCount":68},[],{"trials":379,"activeCount":68},[380],{"nctId":381,"briefTitle":382,"status":78,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":390},"NCT00702117","Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias",[60],"2010-01","2008-06",123,[15,388,389],"Tachycardia, Ventricular","Brugada Syndrome",[368,391,392],"ajmaline","procainamide",{"trials":394,"activeCount":68},[],{"intervention":391,"totalTrials":95,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":411},{"trials":398,"activeCount":68},[],{"trials":400,"activeCount":68},[],{"trials":402,"activeCount":68},[],{"trials":404,"activeCount":68},[],{"trials":406,"activeCount":68},[407],{"nctId":381,"briefTitle":382,"status":78,"phases":408,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":409,"interventions":410},[60],[15,388,389],[368,391,392],{"trials":412,"activeCount":68},[],{"intervention":392,"totalTrials":95,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":429},{"trials":416,"activeCount":68},[],{"trials":418,"activeCount":68},[],{"trials":420,"activeCount":68},[],{"trials":422,"activeCount":68},[],{"trials":424,"activeCount":68},[425],{"nctId":381,"briefTitle":382,"status":78,"phases":426,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":427,"interventions":428},[60],[15,388,389],[368,391,392],{"trials":430,"activeCount":68},[],{"intervention":432,"totalTrials":95,"cells":433},"Beta blocker\u002Fdigoxine\u002Famiodarone",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":456},{"trials":435,"activeCount":68},[],{"trials":437,"activeCount":68},[],{"trials":439,"activeCount":68},[],{"trials":441,"activeCount":68},[],{"trials":443,"activeCount":68},[444],{"nctId":445,"briefTitle":446,"status":78,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":455},"NCT01181414","Spanish Atrial Fibrillation And Resynchronization Study",[60],"2014-11","2015-01","2010-10",60,[453,454,15],"Chronic Heart Failure","Cardiomyopathy, Dilated",[432],{"trials":457,"activeCount":68},[],{"intervention":459,"totalTrials":95,"cells":460},"Plenvu",{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":480},{"trials":462,"activeCount":68},[],{"trials":464,"activeCount":68},[],{"trials":466,"activeCount":68},[],{"trials":468,"activeCount":68},[],{"trials":470,"activeCount":68},[471],{"nctId":472,"briefTitle":473,"status":78,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":479},"NCT04297423","Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy",[60],"2022-06-28","2020-03-11",1002,[28],[459],{"trials":481,"activeCount":68},[],{"intervention":483,"totalTrials":95,"cells":484},"Enfuvirtide",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":503},{"trials":486,"activeCount":68},[],{"trials":488,"activeCount":68},[],{"trials":490,"activeCount":68},[],{"trials":492,"activeCount":68},[],{"trials":494,"activeCount":68},[495],{"nctId":496,"briefTitle":497,"status":78,"phases":498,"primaryCompletion":499,"completion":499,"start":358,"enrollment":500,"conditions":501,"interventions":502},"NCT00657761","Metabolic Effects of Enfuvirtide in Healthy Volunteers",[60],"2006-03",15,[18],[483],{"trials":504,"activeCount":68},[],{"intervention":278,"totalTrials":95,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":521},{"trials":508,"activeCount":68},[],{"trials":510,"activeCount":68},[],{"trials":512,"activeCount":68},[],{"trials":514,"activeCount":68},[],{"trials":516,"activeCount":68},[517],{"nctId":270,"briefTitle":271,"status":78,"phases":518,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":519,"interventions":520},[60],[24],[278,257],{"trials":522,"activeCount":68},[],{"intervention":524,"totalTrials":95,"cells":525},"Delstrigo",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":534,"NA":546},{"trials":527,"activeCount":68},[],{"trials":529,"activeCount":68},[],{"trials":531,"activeCount":68},[],{"trials":533,"activeCount":68},[],{"trials":535,"activeCount":68},[536],{"nctId":537,"briefTitle":538,"status":78,"phases":539,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT04233372","Evaluation of (Doravirine \u002F Lamivudine \u002F Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study",[60],"2022-07-28","2020-08-27",399,[544],"Hiv",[524],{"trials":547,"activeCount":68},[],{"intervention":549,"totalTrials":95,"cells":550},"Insulin",{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":573},{"trials":552,"activeCount":68},[],{"trials":554,"activeCount":68},[],{"trials":556,"activeCount":68},[],{"trials":558,"activeCount":68},[],{"trials":560,"activeCount":68},[561],{"nctId":562,"briefTitle":563,"status":78,"phases":564,"primaryCompletion":565,"completion":310,"start":566,"enrollment":567,"conditions":568,"interventions":572},"NCT00362778","Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia",[60],"2006-12","2006-01",28,[569,570,571],"Diabetes","Hyperglycemia","Acute Myocardial Infarction",[549],{"trials":574,"activeCount":68},[],{"intervention":576,"totalTrials":95,"cells":577},"Clopidogrel",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":586,"NA":600},{"trials":579,"activeCount":68},[],{"trials":581,"activeCount":68},[],{"trials":583,"activeCount":68},[],{"trials":585,"activeCount":68},[],{"trials":587,"activeCount":68},[588],{"nctId":589,"briefTitle":590,"status":78,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":598},"NCT02211066","TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization",[60],"2019-06","2019-06-12","2014-10",59,[597],"Patients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion)",[576,599],"Ticagrelor",{"trials":601,"activeCount":68},[],{"intervention":599,"totalTrials":95,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":612,"NA":618},{"trials":605,"activeCount":68},[],{"trials":607,"activeCount":68},[],{"trials":609,"activeCount":68},[],{"trials":611,"activeCount":68},[],{"trials":613,"activeCount":68},[614],{"nctId":589,"briefTitle":590,"status":78,"phases":615,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":616,"interventions":617},[60],[597],[576,599],{"trials":619,"activeCount":68},[],{"intervention":621,"totalTrials":95,"cells":622},"Pegylated interferon and ribavirin",{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":631,"NA":642},{"trials":624,"activeCount":68},[],{"trials":626,"activeCount":68},[],{"trials":628,"activeCount":68},[],{"trials":630,"activeCount":68},[],{"trials":632,"activeCount":68},[633],{"nctId":634,"briefTitle":635,"status":78,"phases":636,"completion":499,"start":637,"enrollment":638,"conditions":639,"interventions":641},"NCT00383864","Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.",[60],"2001-07",55,[640],"Hepatitis C",[621],{"trials":643,"activeCount":68},[],{"intervention":645,"totalTrials":95,"cells":646},"Oral norfloxacin",{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":666},{"trials":648,"activeCount":68},[],{"trials":650,"activeCount":68},[],{"trials":652,"activeCount":68},[],{"trials":654,"activeCount":68},[],{"trials":656,"activeCount":68},[657],{"nctId":658,"briefTitle":659,"status":78,"phases":660,"completion":661,"start":662,"enrollment":359,"conditions":663,"interventions":665},"NCT00359853","Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis",[60],"2005-03","2000-09",[664,252,21],"Spontaneous Bacterial Peritonitis",[645],{"trials":667,"activeCount":68},[],{"intervention":669,"totalTrials":95,"cells":670},"Indacaterol",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":689},{"trials":672,"activeCount":68},[],{"trials":674,"activeCount":68},[],{"trials":676,"activeCount":68},[],{"trials":678,"activeCount":68},[],{"trials":680,"activeCount":68},[681],{"nctId":682,"briefTitle":683,"status":345,"phases":684,"primaryCompletion":685,"completion":686,"start":685,"enrollment":311,"conditions":687,"interventions":688},"NCT02547558","Pulmonary Gas Exchange Response to Indacaterol in COPD",[60],"2015-10","2015-11",[313],[669],{"trials":690,"activeCount":68},[],{"intervention":692,"totalTrials":95,"cells":693},"Losartan",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":702,"NA":713},{"trials":695,"activeCount":68},[],{"trials":697,"activeCount":68},[],{"trials":699,"activeCount":68},[],{"trials":701,"activeCount":68},[],{"trials":703,"activeCount":68},[704],{"nctId":705,"briefTitle":706,"status":78,"phases":707,"completion":566,"start":708,"enrollment":311,"conditions":709,"interventions":712},"NCT00298714","Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C",[60],"2003-03",[710,711],"Chronic Hepatitis C","Liver Fibrosis",[692],{"trials":714,"activeCount":68},[],{"intervention":716,"totalTrials":95,"cells":717},"Ospemifene 60 mg",{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":741},{"trials":719,"activeCount":68},[],{"trials":721,"activeCount":68},[],{"trials":723,"activeCount":68},[],{"trials":725,"activeCount":68},[],{"trials":727,"activeCount":68},[728],{"nctId":729,"briefTitle":730,"status":78,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":740},"NCT04677491","Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders",[60],"2022-11-01","2023-12-01","2021-11-01",25,[737,738,739],"Vulvovaginal Signs and Symptoms","Genitourinary Syndrome of Menopause","Sexual; Disorder, Arousal, Female",[716],{"trials":742,"activeCount":68},[],{"intervention":744,"totalTrials":95,"cells":745},"Prasterone (DHEA), Micronized",{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":754,"NA":766},{"trials":747,"activeCount":68},[],{"trials":749,"activeCount":68},[],{"trials":751,"activeCount":68},[],{"trials":753,"activeCount":68},[],{"trials":755,"activeCount":68},[756],{"nctId":757,"briefTitle":758,"status":78,"phases":759,"primaryCompletion":760,"completion":761,"start":762,"enrollment":19,"conditions":763,"interventions":765},"NCT04705883","Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors",[60],"2021-11-08","2021-12-01","2020-09-01",[764,31,738],"Vulvar Atrophy",[744],{"trials":767,"activeCount":68},[],{"intervention":769,"totalTrials":95,"cells":770},"Combivir+Kaletra",{"EARLY_PHASE1":771,"PHASE1":773,"PHASE2":775,"PHASE3":777,"PHASE4":779,"NA":791},{"trials":772,"activeCount":68},[],{"trials":774,"activeCount":68},[],{"trials":776,"activeCount":68},[],{"trials":778,"activeCount":68},[],{"trials":780,"activeCount":68},[781],{"nctId":782,"briefTitle":783,"status":78,"phases":784,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":789},"NCT00385645","Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis",[60],"2009-08","2006-05",255,[18],[769,790],"Combivir+Reyataz",{"trials":792,"activeCount":68},[],{"intervention":790,"totalTrials":95,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":803,"NA":809},{"trials":796,"activeCount":68},[],{"trials":798,"activeCount":68},[],{"trials":800,"activeCount":68},[],{"trials":802,"activeCount":68},[],{"trials":804,"activeCount":68},[805],{"nctId":782,"briefTitle":783,"status":78,"phases":806,"primaryCompletion":785,"completion":785,"start":786,"enrollment":787,"conditions":807,"interventions":808},[60],[18],[769,790],{"trials":810,"activeCount":68},[],{"intervention":812,"totalTrials":95,"cells":813},"Maraviroc",{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":831},{"trials":815,"activeCount":68},[],{"trials":817,"activeCount":68},[],{"trials":819,"activeCount":68},[],{"trials":821,"activeCount":68},[],{"trials":823,"activeCount":68},[824],{"nctId":825,"briefTitle":826,"status":345,"phases":827,"enrollment":451,"conditions":828,"interventions":830},"NCT01235013","Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells\u002Fmm3",[60],[829],"HIV-1 Infection",[812],{"trials":832,"activeCount":68},[],{"intervention":834,"totalTrials":95,"cells":835},"Multimodal intervention on sexual dysfunction and quality-of-life",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":858},{"trials":837,"activeCount":68},[],{"trials":839,"activeCount":68},[],{"trials":841,"activeCount":68},[],{"trials":843,"activeCount":68},[],{"trials":845,"activeCount":68},[846],{"nctId":847,"briefTitle":848,"status":345,"phases":849,"primaryCompletion":850,"completion":851,"start":142,"enrollment":852,"conditions":853,"interventions":857},"NCT06031493","A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)",[60],"2025-02","2025-04",122,[854,855,856],"Cervical Cancer","Sexual Dysfunction","Quality of Life",[834],{"trials":859,"activeCount":68},[],{"intervention":861,"totalTrials":95,"cells":862},"drops intilation",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":885},{"trials":864,"activeCount":68},[],{"trials":866,"activeCount":68},[],{"trials":868,"activeCount":68},[],{"trials":870,"activeCount":68},[],{"trials":872,"activeCount":68},[873],{"nctId":874,"briefTitle":875,"status":78,"phases":876,"primaryCompletion":877,"start":878,"enrollment":879,"conditions":880,"interventions":884},"NCT00765635","Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal",[60],"2008-10","2008-09",90,[881,882,883],"Ear Infection","Hearing Loss","Vertigo",[861,861,861],{"trials":886,"activeCount":68},[],{"intervention":888,"totalTrials":95,"cells":889},"Hyoscine bromide",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":911},{"trials":891,"activeCount":68},[],{"trials":893,"activeCount":68},[],{"trials":895,"activeCount":68},[],{"trials":897,"activeCount":68},[],{"trials":899,"activeCount":68},[900],{"nctId":901,"briefTitle":902,"status":246,"phases":903,"primaryCompletion":904,"completion":904,"start":905,"enrollment":906,"conditions":907,"interventions":909},"NCT02103166","Role of Hyoscine Bromide in Latent and Active Labor",[60],"2018-04","2014-04",180,[908],"Labor, First Stage",[888,910],"Physiological serum",{"trials":912,"activeCount":68},[],{"intervention":910,"totalTrials":95,"cells":914},{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":923,"NA":929},{"trials":916,"activeCount":68},[],{"trials":918,"activeCount":68},[],{"trials":920,"activeCount":68},[],{"trials":922,"activeCount":68},[],{"trials":924,"activeCount":68},[925],{"nctId":901,"briefTitle":902,"status":246,"phases":926,"primaryCompletion":904,"completion":904,"start":905,"enrollment":906,"conditions":927,"interventions":928},[60],[908],[888,910],{"trials":930,"activeCount":68},[],{"intervention":932,"totalTrials":95,"cells":933},"Hepatitis A",{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":959},{"trials":935,"activeCount":68},[],{"trials":937,"activeCount":68},[],{"trials":939,"activeCount":68},[],{"trials":941,"activeCount":68},[],{"trials":943,"activeCount":68},[944],{"nctId":945,"briefTitle":946,"status":78,"phases":947,"completion":499,"start":948,"enrollment":949,"conditions":950,"interventions":952},"NCT00329251","Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV",[60],"2003-04",26,[951],"HIV",[932,953,954,955,956,957,958],"Hepatitis B","Influenza","Pneumococcal","Tetanus-diphteria","Varicella","Measles-Mumps-Rubella",{"trials":960,"activeCount":68},[],{"intervention":953,"totalTrials":95,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":971,"NA":977},{"trials":964,"activeCount":68},[],{"trials":966,"activeCount":68},[],{"trials":968,"activeCount":68},[],{"trials":970,"activeCount":68},[],{"trials":972,"activeCount":68},[973],{"nctId":945,"briefTitle":946,"status":78,"phases":974,"completion":499,"start":948,"enrollment":949,"conditions":975,"interventions":976},[60],[951],[932,953,954,955,956,957,958],{"trials":978,"activeCount":68},[],{"intervention":954,"totalTrials":95,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":989,"NA":995},{"trials":982,"activeCount":68},[],{"trials":984,"activeCount":68},[],{"trials":986,"activeCount":68},[],{"trials":988,"activeCount":68},[],{"trials":990,"activeCount":68},[991],{"nctId":945,"briefTitle":946,"status":78,"phases":992,"completion":499,"start":948,"enrollment":949,"conditions":993,"interventions":994},[60],[951],[932,953,954,955,956,957,958],{"trials":996,"activeCount":68},[],{"intervention":955,"totalTrials":95,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1005,"PHASE4":1007,"NA":1013},{"trials":1000,"activeCount":68},[],{"trials":1002,"activeCount":68},[],{"trials":1004,"activeCount":68},[],{"trials":1006,"activeCount":68},[],{"trials":1008,"activeCount":68},[1009],{"nctId":945,"briefTitle":946,"status":78,"phases":1010,"completion":499,"start":948,"enrollment":949,"conditions":1011,"interventions":1012},[60],[951],[932,953,954,955,956,957,958],{"trials":1014,"activeCount":68},[],{"intervention":956,"totalTrials":95,"cells":1016},{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1031},{"trials":1018,"activeCount":68},[],{"trials":1020,"activeCount":68},[],{"trials":1022,"activeCount":68},[],{"trials":1024,"activeCount":68},[],{"trials":1026,"activeCount":68},[1027],{"nctId":945,"briefTitle":946,"status":78,"phases":1028,"completion":499,"start":948,"enrollment":949,"conditions":1029,"interventions":1030},[60],[951],[932,953,954,955,956,957,958],{"trials":1032,"activeCount":68},[],{"intervention":957,"totalTrials":95,"cells":1034},{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1049},{"trials":1036,"activeCount":68},[],{"trials":1038,"activeCount":68},[],{"trials":1040,"activeCount":68},[],{"trials":1042,"activeCount":68},[],{"trials":1044,"activeCount":68},[1045],{"nctId":945,"briefTitle":946,"status":78,"phases":1046,"completion":499,"start":948,"enrollment":949,"conditions":1047,"interventions":1048},[60],[951],[932,953,954,955,956,957,958],{"trials":1050,"activeCount":68},[],{"intervention":958,"totalTrials":95,"cells":1052},{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1061,"NA":1067},{"trials":1054,"activeCount":68},[],{"trials":1056,"activeCount":68},[],{"trials":1058,"activeCount":68},[],{"trials":1060,"activeCount":68},[],{"trials":1062,"activeCount":68},[1063],{"nctId":945,"briefTitle":946,"status":78,"phases":1064,"completion":499,"start":948,"enrollment":949,"conditions":1065,"interventions":1066},[60],[951],[932,953,954,955,956,957,958],{"trials":1068,"activeCount":68},[],{"intervention":1070,"totalTrials":95,"cells":1071},"methylprednisolone",{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1092},{"trials":1073,"activeCount":68},[],{"trials":1075,"activeCount":68},[],{"trials":1077,"activeCount":68},[],{"trials":1079,"activeCount":68},[],{"trials":1081,"activeCount":68},[1082],{"nctId":1083,"briefTitle":1084,"status":78,"phases":1085,"primaryCompletion":274,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1091},"NCT00908713","Corticoids in Severe Community-Acquired Pneumonia (CAP)",[60],"2012-03","2004-01",120,[1090],"Community-Acquired Pneumonia",[1070],{"trials":1093,"activeCount":68},[],{"intervention":1095,"totalTrials":95,"cells":1096},"tenofovir + abacavir + lopinavir\u002Fritonavir",{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1115},{"trials":1098,"activeCount":68},[],{"trials":1100,"activeCount":68},[],{"trials":1102,"activeCount":68},[],{"trials":1104,"activeCount":68},[],{"trials":1106,"activeCount":68},[1107],{"nctId":1108,"briefTitle":1109,"status":1110,"phases":1111,"enrollment":451,"conditions":1112,"interventions":1113},"NCT00386659","Immune Reconstitution in naïve HIV Patients With CD4 \u003C100 Cells\u002FmL When Treated With Lopinavir or Efavirenz.","TERMINATED",[60],[24],[1095,1114],"tenofovir + abacavir + efavirenz",{"trials":1116,"activeCount":68},[],{"intervention":1114,"totalTrials":95,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1133},{"trials":1120,"activeCount":68},[],{"trials":1122,"activeCount":68},[],{"trials":1124,"activeCount":68},[],{"trials":1126,"activeCount":68},[],{"trials":1128,"activeCount":68},[1129],{"nctId":1108,"briefTitle":1109,"status":1110,"phases":1130,"enrollment":451,"conditions":1131,"interventions":1132},[60],[24],[1095,1114],{"trials":1134,"activeCount":68},[],{"intervention":364,"totalTrials":95,"cells":1136},{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1151},{"trials":1138,"activeCount":68},[],{"trials":1140,"activeCount":68},[],{"trials":1142,"activeCount":68},[],{"trials":1144,"activeCount":68},[],{"trials":1146,"activeCount":68},[1147],{"nctId":354,"briefTitle":355,"status":78,"phases":1148,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":1149,"interventions":1150},[60],[361,362],[330,364],{"trials":1152,"activeCount":68},[],{"intervention":1154,"totalTrials":95,"cells":1155},"albumin",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1162,"PHASE4":1164,"NA":1180},{"trials":1157,"activeCount":68},[],{"trials":1159,"activeCount":68},[],{"trials":1161,"activeCount":68},[],{"trials":1163,"activeCount":68},[],{"trials":1165,"activeCount":68},[1166],{"nctId":1167,"briefTitle":1168,"status":78,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":322,"enrollment":1171,"conditions":1172,"interventions":1178},"NCT00839358","Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation",[60],"2016-02",199,[1173,1174,1175,1176,1177],"Renal Failure","Hyponatremia","Sepsis","Hepatic Encephalopathy","Gastrointestinal Bleeding",[1154,1179],"Midodrine",{"trials":1181,"activeCount":68},[],{"intervention":1179,"totalTrials":95,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1198},{"trials":1185,"activeCount":68},[],{"trials":1187,"activeCount":68},[],{"trials":1189,"activeCount":68},[],{"trials":1191,"activeCount":68},[],{"trials":1193,"activeCount":68},[1194],{"nctId":1167,"briefTitle":1168,"status":78,"phases":1195,"primaryCompletion":1170,"completion":1170,"start":322,"enrollment":1171,"conditions":1196,"interventions":1197},[60],[1173,1174,1175,1176,1177],[1154,1179],{"trials":1199,"activeCount":68},[],{"intervention":1201,"totalTrials":95,"cells":1202},"Antiarrhythmic drug",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1221},{"trials":1204,"activeCount":68},[],{"trials":1206,"activeCount":68},[],{"trials":1208,"activeCount":68},[],{"trials":1210,"activeCount":68},[],{"trials":1212,"activeCount":68},[1213],{"nctId":1214,"briefTitle":1215,"status":78,"phases":1216,"primaryCompletion":320,"completion":232,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT00863213","Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation",[60],"2009-03",152,[15],[1201],{"trials":1222,"activeCount":68},[],{"intervention":1224,"totalTrials":95,"cells":1225},"Progesterone",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1234,"NA":1245},{"trials":1227,"activeCount":68},[],{"trials":1229,"activeCount":68},[],{"trials":1231,"activeCount":68},[],{"trials":1233,"activeCount":68},[],{"trials":1235,"activeCount":68},[1236],{"nctId":1237,"briefTitle":1238,"status":78,"phases":1239,"primaryCompletion":1240,"completion":1240,"start":385,"enrollment":1241,"conditions":1242,"interventions":1244},"NCT00646802","Vaginal PROgesterone as Maintenance Treatment After an epISode of prEterm Labor (PROMISE Study)",[60],"2012-05",265,[1243],"Threatened Premature Labor",[1224],{"trials":1246,"activeCount":68},[],{"intervention":1248,"totalTrials":95,"cells":1249},"cefuroxime",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1270},{"trials":1251,"activeCount":68},[],{"trials":1253,"activeCount":68},[],{"trials":1255,"activeCount":68},[],{"trials":1257,"activeCount":68},[],{"trials":1259,"activeCount":68},[1260],{"nctId":1261,"briefTitle":1262,"status":78,"phases":1263,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1269},"NCT00497341","Antibiotic Prophylaxis in Total Knee Prosthesis",[60],"2010-08","2008-01",1332,[1268],"Infection",[1248],{"trials":1271,"activeCount":68},[],{"intervention":1273,"totalTrials":95,"cells":1274},"Ketamine",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1296},{"trials":1276,"activeCount":68},[],{"trials":1278,"activeCount":68},[],{"trials":1280,"activeCount":68},[],{"trials":1282,"activeCount":68},[],{"trials":1284,"activeCount":68},[1285],{"nctId":1286,"briefTitle":1287,"status":78,"phases":1288,"primaryCompletion":1289,"completion":1290,"start":878,"enrollment":1291,"conditions":1292,"interventions":1295},"NCT01243801","Prevention of Persistent Postsurgical Pain After Thoracotomy",[60],"2011-10","2011-12",104,[1293,1294],"Persistent Pain","Postoperative Hyperalgesia",[1273],{"trials":1297,"activeCount":68},[],{"intervention":1299,"totalTrials":95,"cells":1300},"Disodium pamidronate",{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1309,"NA":1321},{"trials":1302,"activeCount":68},[],{"trials":1304,"activeCount":68},[],{"trials":1306,"activeCount":68},[],{"trials":1308,"activeCount":68},[],{"trials":1310,"activeCount":68},[1311],{"nctId":1312,"briefTitle":1313,"status":78,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT00657852","Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant",[60],"2003-12","2000-12",79,[1319],"Bone Disease, Metabolic",[1299],{"trials":1322,"activeCount":68},[],{"intervention":1324,"totalTrials":95,"cells":1325},"AZT+3TC+IDV+RTV",{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1332,"PHASE4":1334,"NA":1343},{"trials":1327,"activeCount":68},[],{"trials":1329,"activeCount":68},[],{"trials":1331,"activeCount":68},[],{"trials":1333,"activeCount":68},[],{"trials":1335,"activeCount":68},[1336],{"nctId":1337,"briefTitle":1338,"status":78,"phases":1339,"enrollment":359,"conditions":1340,"interventions":1341},"NCT00385957","Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100",[60],[18],[1324,1342],"AZT+3TC+EFV",{"trials":1344,"activeCount":68},[],{"intervention":1342,"totalTrials":95,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1355,"NA":1361},{"trials":1348,"activeCount":68},[],{"trials":1350,"activeCount":68},[],{"trials":1352,"activeCount":68},[],{"trials":1354,"activeCount":68},[],{"trials":1356,"activeCount":68},[1357],{"nctId":1337,"briefTitle":1338,"status":78,"phases":1358,"enrollment":359,"conditions":1359,"interventions":1360},[60],[18],[1324,1342],{"trials":1362,"activeCount":68},[],{"intervention":1364,"totalTrials":95,"cells":1365},"Standard continuous antiretroviral therapy",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1372,"PHASE4":1374,"NA":1389},{"trials":1367,"activeCount":68},[],{"trials":1369,"activeCount":68},[],{"trials":1371,"activeCount":68},[],{"trials":1373,"activeCount":68},[],{"trials":1375,"activeCount":68},[1376],{"nctId":1377,"briefTitle":1378,"status":78,"phases":1379,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":1384,"interventions":1386},"NCT00646984","Strategies of Interruption\u002FReinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy",[60],"2005-04","2006-04","2002-01",147,[1385],"HIV-Associated Lipodystrophy Syndrome",[1364,1387,1388],"CD-4 guided therapy interruption","Viral load driven treatment interruption",{"trials":1390,"activeCount":68},[],{"intervention":1387,"totalTrials":95,"cells":1392},{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1401,"NA":1407},{"trials":1394,"activeCount":68},[],{"trials":1396,"activeCount":68},[],{"trials":1398,"activeCount":68},[],{"trials":1400,"activeCount":68},[],{"trials":1402,"activeCount":68},[1403],{"nctId":1377,"briefTitle":1378,"status":78,"phases":1404,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":1405,"interventions":1406},[60],[1385],[1364,1387,1388],{"trials":1408,"activeCount":68},[],{"intervention":1388,"totalTrials":95,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1425},{"trials":1412,"activeCount":68},[],{"trials":1414,"activeCount":68},[],{"trials":1416,"activeCount":68},[],{"trials":1418,"activeCount":68},[],{"trials":1420,"activeCount":68},[1421],{"nctId":1377,"briefTitle":1378,"status":78,"phases":1422,"primaryCompletion":1380,"completion":1381,"start":1382,"enrollment":1383,"conditions":1423,"interventions":1424},[60],[1385],[1364,1387,1388],{"trials":1426,"activeCount":68},[],{"intervention":288,"totalTrials":95,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1437,"NA":1443},{"trials":1430,"activeCount":68},[],{"trials":1432,"activeCount":68},[],{"trials":1434,"activeCount":68},[],{"trials":1436,"activeCount":68},[],{"trials":1438,"activeCount":68},[1439],{"nctId":280,"briefTitle":281,"status":78,"phases":1440,"primaryCompletion":283,"completion":283,"start":284,"enrollment":275,"conditions":1441,"interventions":1442},[60],[24],[287,288],{"trials":1444,"activeCount":68},[],{"intervention":1446,"totalTrials":95,"cells":1447},"Poractant Alfa Intratracheal Suspension [Curosurf]",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1454,"PHASE4":1470,"NA":1472},{"trials":1449,"activeCount":68},[],{"trials":1451,"activeCount":68},[],{"trials":1453,"activeCount":68},[],{"trials":1455,"activeCount":68},[1456],{"nctId":1457,"briefTitle":1458,"status":345,"phases":1459,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1468},"NCT04862377","Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.",[59],"2024-04-01","2026-04-01","2021-10-01",50,[1465,1466,1467],"Bronchopulmonary Dysplasia","Respiratory Distress Syndrome in Premature Infant","Prematurity",[1446,1469],"Budesonide 0.5 MG\u002FML",{"trials":1471,"activeCount":68},[],{"trials":1473,"activeCount":68},[],{"intervention":1469,"totalTrials":95,"cells":1475},{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1488,"NA":1490},{"trials":1477,"activeCount":68},[],{"trials":1479,"activeCount":68},[],{"trials":1481,"activeCount":68},[],{"trials":1483,"activeCount":68},[1484],{"nctId":1457,"briefTitle":1458,"status":345,"phases":1485,"primaryCompletion":1460,"completion":1461,"start":1462,"enrollment":1463,"conditions":1486,"interventions":1487},[59],[1465,1466,1467],[1446,1469],{"trials":1489,"activeCount":68},[],{"trials":1491,"activeCount":68},[],{"intervention":240,"totalTrials":95,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1506,"NA":1508},{"trials":1495,"activeCount":68},[],{"trials":1497,"activeCount":68},[],{"trials":1499,"activeCount":68},[],{"trials":1501,"activeCount":68},[1502],{"nctId":229,"briefTitle":230,"status":78,"phases":1503,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":1504,"interventions":1505},[58,59],[236,237],[239,240],{"trials":1507,"activeCount":68},[],{"trials":1509,"activeCount":68},[],{"intervention":1511,"totalTrials":95,"cells":1512},"bevacizumab",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1531,"NA":1533},{"trials":1514,"activeCount":68},[],{"trials":1516,"activeCount":68},[],{"trials":1518,"activeCount":68},[],{"trials":1520,"activeCount":68},[1521],{"nctId":1522,"briefTitle":1523,"status":1110,"phases":1524,"primaryCompletion":1525,"completion":1525,"start":1526,"enrollment":29,"conditions":1527,"interventions":1529},"NCT01095809","Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema",[59],"2013-04","2010-04",[1528],"Uveitis",[1511,1530],"triamcinolone acetonide",{"trials":1532,"activeCount":68},[],{"trials":1534,"activeCount":68},[],{"intervention":1530,"totalTrials":95,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1549,"NA":1551},{"trials":1538,"activeCount":68},[],{"trials":1540,"activeCount":68},[],{"trials":1542,"activeCount":68},[],{"trials":1544,"activeCount":68},[1545],{"nctId":1522,"briefTitle":1523,"status":1110,"phases":1546,"primaryCompletion":1525,"completion":1525,"start":1526,"enrollment":29,"conditions":1547,"interventions":1548},[59],[1528],[1511,1530],{"trials":1550,"activeCount":68},[],{"trials":1552,"activeCount":68},[],{"intervention":1554,"totalTrials":95,"cells":1555},"Human Albumin",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1572,"NA":1574},{"trials":1557,"activeCount":68},[],{"trials":1559,"activeCount":68},[],{"trials":1561,"activeCount":68},[],{"trials":1563,"activeCount":68},[1564],{"nctId":1565,"briefTitle":1566,"status":78,"phases":1567,"primaryCompletion":877,"completion":877,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1571},"NCT00124228","Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis",[59],"2004-11",110,[21],[1554],{"trials":1573,"activeCount":68},[],{"trials":1575,"activeCount":68},[],{"intervention":1577,"totalTrials":95,"cells":1578},"The intervention involves the discontinuation of the opioid.",{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1585,"PHASE4":1597,"NA":1599},{"trials":1580,"activeCount":68},[],{"trials":1582,"activeCount":68},[],{"trials":1584,"activeCount":68},[],{"trials":1586,"activeCount":68},[1587],{"nctId":1588,"briefTitle":1589,"status":78,"phases":1590,"primaryCompletion":1591,"completion":1592,"start":1593,"enrollment":311,"conditions":1594,"interventions":1596},"NCT06522633","Esophageal Dysfunction Associated With Opioids: Clinical Response and Manometric Findings After Opioid Discontinuation",[59],"2024-02-01","2024-08-31","2020-11-01",[1595],"Opioid Use",[1577],{"trials":1598,"activeCount":68},[],{"trials":1600,"activeCount":68},[],{"intervention":1602,"totalTrials":95,"cells":1603},"Enalapril and carvedilol",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1625,"NA":1627},{"trials":1605,"activeCount":68},[],{"trials":1607,"activeCount":68},[],{"trials":1609,"activeCount":68},[],{"trials":1611,"activeCount":68},[1612],{"nctId":1613,"briefTitle":1614,"status":78,"phases":1615,"primaryCompletion":1290,"completion":1086,"start":1616,"enrollment":879,"conditions":1617,"interventions":1624},"NCT01110824","Prevention of Left Ventricular Dysfunction During Chemotherapy",[59],"2008-04",[1618,1619,1620,1621,1622,1623],"Acute Myeloid Leukemia","Precursor-cell Lymphoblastic Leukemia-Lymphoma","Lymphoid Neoplasm","Multiple Myeloma","Lymphoma","Autologous Hematopoietic Stem Cell Transplantation",[1602],{"trials":1626,"activeCount":68},[],{"trials":1628,"activeCount":68},[],{"intervention":1630,"totalTrials":95,"cells":1631},"pentoxifylline",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1648,"NA":1650},{"trials":1633,"activeCount":68},[],{"trials":1635,"activeCount":68},[],{"trials":1637,"activeCount":68},[],{"trials":1639,"activeCount":68},[1640],{"nctId":1641,"briefTitle":1642,"status":78,"phases":1643,"primaryCompletion":565,"completion":565,"start":1644,"enrollment":1291,"conditions":1645,"interventions":1647},"NCT00632697","Pentoxifylline and Endometriosis",[59],"2001-10",[1646],"Endometriosis-Associated Infertility",[1630],{"trials":1649,"activeCount":68},[],{"trials":1651,"activeCount":68},[],{"intervention":1653,"totalTrials":95,"cells":1654},"Intensive Medical Treatment",{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1671,"NA":1673},{"trials":1656,"activeCount":68},[],{"trials":1658,"activeCount":68},[],{"trials":1660,"activeCount":68},[],{"trials":1662,"activeCount":68},[1663],{"nctId":1664,"briefTitle":1665,"status":345,"phases":1666,"enrollment":275,"conditions":1667,"interventions":1670},"NCT01353066","Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM)",[58,59],[1668,1669],"Atherosclerotic Cardiovascular Disease","Subclinical Disease and\u002For Syndrome",[1653],{"trials":1672,"activeCount":68},[],{"trials":1674,"activeCount":68},[],{"intervention":1676,"totalTrials":95,"cells":1677},"boosted PI",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1695,"NA":1697},{"trials":1679,"activeCount":68},[],{"trials":1681,"activeCount":68},[],{"trials":1683,"activeCount":68},[],{"trials":1685,"activeCount":68},[1686],{"nctId":1687,"briefTitle":1688,"status":78,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1265,"enrollment":1691,"conditions":1692,"interventions":1693},"NCT00528892","Switching From PI to RALtegravir in HIV Stable Patients",[59],"2010-03",282,[18],[1694,1676],"Raltegravir",{"trials":1696,"activeCount":68},[],{"trials":1698,"activeCount":68},[],{"intervention":1700,"totalTrials":95,"cells":1701},"Transdermal testosterone",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1708,"PHASE4":1717,"NA":1719},{"trials":1703,"activeCount":68},[],{"trials":1705,"activeCount":68},[],{"trials":1707,"activeCount":68},[],{"trials":1709,"activeCount":68},[1710],{"nctId":1711,"briefTitle":1712,"status":78,"phases":1713,"start":248,"conditions":1714,"interventions":1716},"NCT00693108","Androgens for Poor Responders in In Vitro Fertilization",[59],[1715],"Ovarian Response",[1700],{"trials":1718,"activeCount":68},[],{"trials":1720,"activeCount":68},[],{"intervention":1722,"totalTrials":95,"cells":1723},"Hepatitis B vaccine",{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1741,"PHASE4":1743,"NA":1745},{"trials":1725,"activeCount":68},[],{"trials":1727,"activeCount":68},[],{"trials":1729,"activeCount":68},[1730],{"nctId":1731,"briefTitle":1732,"status":345,"phases":1733,"primaryCompletion":1734,"completion":1735,"start":1736,"enrollment":1737,"conditions":1738,"interventions":1740},"NCT04442841","HBV Vaccine in Anti-core Positive Donors After LT",[58],"2022-01","2023-01","2020-09",114,[1739],"Hepatitis B Reactivation",[1722],{"trials":1742,"activeCount":68},[],{"trials":1744,"activeCount":68},[],{"trials":1746,"activeCount":68},[],{"intervention":1748,"totalTrials":95,"cells":1749},"Dendritic cell vaccine",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1751,"activeCount":68},[],{"trials":1753,"activeCount":68},[],{"trials":1755,"activeCount":68},[1756],{"nctId":1757,"briefTitle":1758,"status":78,"phases":1759,"primaryCompletion":1290,"completion":1290,"start":1760,"enrollment":451,"conditions":1761,"interventions":1762},"NCT00402142","Dendritic Cell Vaccine in HIV-1 Infection",[57,58],"2006-11",[18],[1748,1763,1764,1765,1766],"non pulsed dendritic cell untreated patients","pulsed dendritic cell vaccine","dendritic cell vaccine","non pulsed dendritic cell vaccine",{"trials":1768,"activeCount":68},[],{"trials":1770,"activeCount":68},[],{"trials":1772,"activeCount":68},[],{"intervention":1763,"totalTrials":95,"cells":1774},{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1785,"PHASE4":1787,"NA":1789},{"trials":1776,"activeCount":68},[],{"trials":1778,"activeCount":68},[],{"trials":1780,"activeCount":68},[1781],{"nctId":1757,"briefTitle":1758,"status":78,"phases":1782,"primaryCompletion":1290,"completion":1290,"start":1760,"enrollment":451,"conditions":1783,"interventions":1784},[57,58],[18],[1748,1763,1764,1765,1766],{"trials":1786,"activeCount":68},[],{"trials":1788,"activeCount":68},[],{"trials":1790,"activeCount":68},[],{"intervention":1764,"totalTrials":95,"cells":1792},{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1797,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1794,"activeCount":68},[],{"trials":1796,"activeCount":68},[],{"trials":1798,"activeCount":68},[1799],{"nctId":1757,"briefTitle":1758,"status":78,"phases":1800,"primaryCompletion":1290,"completion":1290,"start":1760,"enrollment":451,"conditions":1801,"interventions":1802},[57,58],[18],[1748,1763,1764,1765,1766],{"trials":1804,"activeCount":68},[],{"trials":1806,"activeCount":68},[],{"trials":1808,"activeCount":68},[],{"intervention":1766,"totalTrials":95,"cells":1810},{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1812,"activeCount":68},[],{"trials":1814,"activeCount":68},[],{"trials":1816,"activeCount":68},[1817],{"nctId":1757,"briefTitle":1758,"status":78,"phases":1818,"primaryCompletion":1290,"completion":1290,"start":1760,"enrollment":451,"conditions":1819,"interventions":1820},[57,58],[18],[1748,1763,1764,1765,1766],{"trials":1822,"activeCount":68},[],{"trials":1824,"activeCount":68},[],{"trials":1826,"activeCount":68},[],{"intervention":1828,"totalTrials":95,"cells":1829},"Cholecalciferol",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1845,"PHASE4":1847,"NA":1849},{"trials":1831,"activeCount":68},[],{"trials":1833,"activeCount":68},[],{"trials":1835,"activeCount":68},[1836],{"nctId":1837,"briefTitle":1838,"status":345,"phases":1839,"enrollment":1840,"conditions":1841,"interventions":1844},"NCT01637155","Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization",[58],44,[26,1842,1843],"Gastric Bypass","Gastrectomy",[1828],{"trials":1846,"activeCount":68},[],{"trials":1848,"activeCount":68},[],{"trials":1850,"activeCount":68},[],{"intervention":1852,"totalTrials":95,"cells":1853},"ATG",{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1869,"PHASE4":1871,"NA":1873},{"trials":1855,"activeCount":68},[],{"trials":1857,"activeCount":68},[],{"trials":1859,"activeCount":68},[1860],{"nctId":1861,"briefTitle":1862,"status":1110,"phases":1863,"primaryCompletion":1864,"start":1865,"enrollment":234,"conditions":1866,"interventions":1868},"NCT00436722","Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial",[58],"2009-07","2006-06",[1867],"Liver Diseases",[1852],{"trials":1870,"activeCount":68},[],{"trials":1872,"activeCount":68},[],{"trials":1874,"activeCount":68},[],{"intervention":1876,"totalTrials":95,"cells":1877},"Sodium Tungstate",{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1879,"activeCount":68},[],{"trials":1881,"activeCount":68},[],{"trials":1883,"activeCount":68},[1884],{"nctId":1885,"briefTitle":1886,"status":78,"phases":1887,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1840,"conditions":1890,"interventions":1891},"NCT00555074","Sodium Tungstate in Obesity",[58],"2009-05","2007-11",[26],[1876],{"trials":1893,"activeCount":68},[],{"trials":1895,"activeCount":68},[],{"trials":1897,"activeCount":68},[],{"intervention":1899,"totalTrials":95,"cells":1900},"Sirolimus",{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1902,"activeCount":68},[],{"trials":1904,"activeCount":68},[],{"trials":1906,"activeCount":68},[1907],{"nctId":1908,"briefTitle":1909,"status":345,"phases":1910,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":1913,"conditions":1914,"interventions":1916},"NCT01034345","Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients",[58],"2011-11","2009-11",52,[1915],"Liver Transplantation",[1899,1917],"Calcineurin inhibitor",{"trials":1919,"activeCount":68},[],{"trials":1921,"activeCount":68},[],{"trials":1923,"activeCount":68},[],{"intervention":1917,"totalTrials":95,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1927,"activeCount":68},[],{"trials":1929,"activeCount":68},[],{"trials":1931,"activeCount":68},[1932],{"nctId":1908,"briefTitle":1909,"status":345,"phases":1933,"primaryCompletion":1911,"completion":1911,"start":1912,"enrollment":1913,"conditions":1934,"interventions":1935},[58],[1915],[1899,1917],{"trials":1937,"activeCount":68},[],{"trials":1939,"activeCount":68},[],{"trials":1941,"activeCount":68},[],{"intervention":1943,"totalTrials":95,"cells":1944},"Simvastatin",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1946,"activeCount":68},[],{"trials":1948,"activeCount":68},[],{"trials":1950,"activeCount":68},[1951],{"nctId":1952,"briefTitle":1953,"status":78,"phases":1954,"primaryCompletion":1955,"completion":1889,"start":1956,"enrollment":595,"conditions":1957,"interventions":1959},"NCT00594191","Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension",[58],"2007-04","2004-03",[21,1958],"Portal Hypertension",[1943],{"trials":1961,"activeCount":68},[],{"trials":1963,"activeCount":68},[],{"trials":1965,"activeCount":68},[],{"intervention":1967,"totalTrials":95,"cells":1968},"Midodrine plus Albumin",{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1970,"activeCount":68},[],{"trials":1972,"activeCount":68},[],{"trials":1974,"activeCount":68},[1975],{"nctId":1976,"briefTitle":1977,"status":78,"phases":1978,"primaryCompletion":1979,"completion":1979,"start":1980,"enrollment":22,"conditions":1981,"interventions":1982},"NCT01133795","Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment",[58],"2016-06","2010-02",[21,1173],[1967],{"trials":1984,"activeCount":68},[],{"trials":1986,"activeCount":68},[],{"trials":1988,"activeCount":68},[],{"intervention":1990,"totalTrials":95,"cells":1991},"Experimental",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":1993,"activeCount":68},[],{"trials":1995,"activeCount":68},[1996],{"nctId":1997,"briefTitle":1998,"status":78,"phases":1999,"primaryCompletion":2000,"completion":2000,"start":2001,"enrollment":9,"conditions":2002,"interventions":2003},"NCT01923610","Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B",[57],"2014-09","2013-09",[18],[1990],{"trials":2005,"activeCount":68},[],{"trials":2007,"activeCount":68},[],{"trials":2009,"activeCount":68},[],{"trials":2011,"activeCount":68},[],{"intervention":2013,"totalTrials":95,"cells":2014},"Risperidone",{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":2016,"activeCount":68},[],{"trials":2018,"activeCount":68},[2019],{"nctId":2020,"briefTitle":2021,"status":345,"phases":2022,"primaryCompletion":1911,"completion":1290,"start":2023,"enrollment":9,"conditions":2024,"interventions":2027},"NCT01259973","Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers",[57],"2011-02",[2025,2026],"Pharmacogenetics","Healthy",[2013,2028],"Haloperidol",{"trials":2030,"activeCount":68},[],{"trials":2032,"activeCount":68},[],{"trials":2034,"activeCount":68},[],{"trials":2036,"activeCount":68},[],{"intervention":2028,"totalTrials":95,"cells":2038},{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2047,"PHASE3":2049,"PHASE4":2051,"NA":2053},{"trials":2040,"activeCount":68},[],{"trials":2042,"activeCount":68},[2043],{"nctId":2020,"briefTitle":2021,"status":345,"phases":2044,"primaryCompletion":1911,"completion":1290,"start":2023,"enrollment":9,"conditions":2045,"interventions":2046},[57],[2025,2026],[2013,2028],{"trials":2048,"activeCount":68},[],{"trials":2050,"activeCount":68},[],{"trials":2052,"activeCount":68},[],{"trials":2054,"activeCount":68},[],{"intervention":2056,"totalTrials":95,"cells":2057},"Vaccination",{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2059,"activeCount":68},[],{"trials":2061,"activeCount":68},[2062],{"nctId":2063,"briefTitle":2064,"status":78,"phases":2065,"primaryCompletion":2066,"completion":2066,"start":2067,"enrollment":2068,"conditions":2069,"interventions":2070},"NCT01571466","A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART",[57],"2013-05","2011-09",30,[24],[2056],{"trials":2072,"activeCount":68},[],{"trials":2074,"activeCount":68},[],{"trials":2076,"activeCount":68},[],{"trials":2078,"activeCount":68},[],{"intervention":1694,"totalTrials":2080,"cells":2081},3,{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2095,"PHASE3":2097,"PHASE4":2103,"NA":2105},{"trials":2083,"activeCount":68},[],{"trials":2085,"activeCount":68},[2086],{"nctId":2087,"briefTitle":2088,"status":345,"phases":2089,"primaryCompletion":320,"completion":320,"start":1690,"enrollment":2090,"conditions":2091,"interventions":2093},"NCT00772720","Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers",[57],14,[2092],"Healthy Volunteers",[2094],"raltegravir",{"trials":2096,"activeCount":68},[],{"trials":2098,"activeCount":68},[2099],{"nctId":1687,"briefTitle":1688,"status":78,"phases":2100,"primaryCompletion":1690,"completion":1690,"start":1265,"enrollment":1691,"conditions":2101,"interventions":2102},[59],[18],[1694,1676],{"trials":2104,"activeCount":68},[],{"trials":2106,"activeCount":68},[2107],{"nctId":2108,"briefTitle":2109,"status":78,"phases":2110,"primaryCompletion":2111,"completion":1290,"start":347,"enrollment":500,"conditions":2112,"interventions":2114},"NCT01258374","Dual Therapy With Raltegravir and Darunavir\u002FRitonavir in HIV Infected Patients.",[],"2011-05",[2113],"Integrase Inhibitors, HIV; HIV PROTEASE INHIB",[1694,2115],"Darunavir",{"intervention":2117,"totalTrials":2080,"cells":2118},"Sulfadoxine-Pyrimethamine",{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2135,"PHASE4":2137,"NA":2139},{"trials":2120,"activeCount":68},[],{"trials":2122,"activeCount":68},[],{"trials":2124,"activeCount":68},[2125],{"nctId":2126,"briefTitle":2127,"status":345,"phases":2128,"completion":2129,"start":2130,"enrollment":2131,"conditions":2132,"interventions":2134},"NCT00209794","IPTi in Mozambican Infants for Malaria Prevention",[57,58],"2005-12","2002-09",1498,[2133],"Malaria",[2117],{"trials":2136,"activeCount":68},[],{"trials":2138,"activeCount":68},[],{"trials":2140,"activeCount":68},[2141,2149],{"nctId":2142,"briefTitle":2143,"status":78,"phases":2144,"primaryCompletion":1217,"completion":1217,"start":358,"enrollment":2145,"conditions":2146,"interventions":2147},"NCT00231452","Age of Exposure and Immunity to Malaria in Infants",[61],349,[2133],[2148],"Sulfadoxine-pyrimethamine",{"nctId":2150,"briefTitle":2151,"status":345,"phases":2152,"completion":565,"start":2153,"enrollment":2154,"conditions":2155,"interventions":2157},"NCT00209781","IPTp Plus ITNs for Malaria Control in Pregnant Women",[61],"2003-08",1028,[2156],"Pregnancy",[2117],{"intervention":2159,"totalTrials":95,"cells":2160},"Deltaprim",{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2162,"activeCount":68},[],{"trials":2164,"activeCount":68},[],{"trials":2166,"activeCount":68},[],{"trials":2168,"activeCount":68},[],{"trials":2170,"activeCount":68},[],{"trials":2172,"activeCount":68},[2173],{"nctId":2174,"briefTitle":2175,"status":1110,"phases":2176,"completion":2177,"start":2178,"enrollment":2179,"conditions":2180,"interventions":2181},"NCT00497471","RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants",[61],"1999-07","1995-02",832,[2133,361],[2159,2182],"iron",{"intervention":2182,"totalTrials":95,"cells":2184},{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2186,"activeCount":68},[],{"trials":2188,"activeCount":68},[],{"trials":2190,"activeCount":68},[],{"trials":2192,"activeCount":68},[],{"trials":2194,"activeCount":68},[],{"trials":2196,"activeCount":68},[2197],{"nctId":2174,"briefTitle":2175,"status":1110,"phases":2198,"completion":2177,"start":2178,"enrollment":2179,"conditions":2199,"interventions":2200},[61],[2133,361],[2159,2182],{"intervention":2202,"totalTrials":95,"cells":2203},"Morphine",{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2205,"activeCount":68},[],{"trials":2207,"activeCount":68},[],{"trials":2209,"activeCount":68},[],{"trials":2211,"activeCount":68},[],{"trials":2213,"activeCount":68},[],{"trials":2215,"activeCount":68},[2216],{"nctId":2217,"briefTitle":2218,"status":345,"phases":2219,"primaryCompletion":2220,"completion":2221,"start":2222,"enrollment":1463,"conditions":2223,"interventions":2227},"NCT05702151","ESP Block in Robotic Cardiac Surgery",[61],"2024-03","2024-06","2022-12-22",[2224,2225,2226],"Heart Valve Diseases","Postoperative Pain, Acute","Analgesia",[2202],{"intervention":2229,"totalTrials":95,"cells":2230},"Dexmedetomidine Injectable Product",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2239,"NA":2241},{"trials":2232,"activeCount":68},[],{"trials":2234,"activeCount":68},[],{"trials":2236,"activeCount":68},[],{"trials":2238,"activeCount":68},[],{"trials":2240,"activeCount":68},[],{"trials":2242,"activeCount":68},[2243],{"nctId":2244,"briefTitle":2245,"status":345,"phases":2246,"primaryCompletion":2247,"completion":2248,"start":2249,"enrollment":2250,"conditions":2251,"interventions":2257},"NCT04358627","Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients",[],"2020-05-30","2020-06-30","2020-04-15",80,[2252,2253,2254,2255,2256],"Acute Respiratory Distress Syndrome","Inflammation","Dexmedetomidine","Cytokine Storm","Delirium, Emergence",[2229],{"intervention":2259,"totalTrials":95,"cells":2260},"resume raltegravir",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2267,"PHASE4":2269,"NA":2271},{"trials":2262,"activeCount":68},[],{"trials":2264,"activeCount":68},[],{"trials":2266,"activeCount":68},[],{"trials":2268,"activeCount":68},[],{"trials":2270,"activeCount":68},[],{"trials":2272,"activeCount":68},[2273],{"nctId":2274,"briefTitle":2275,"status":345,"phases":2276,"primaryCompletion":384,"completion":384,"start":308,"enrollment":311,"conditions":2277,"interventions":2278},"NCT00787774","Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression",[61],[24],[2259],{"intervention":2280,"totalTrials":95,"cells":2281},"Sulphadoxine-pyrimethamine",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2290,"NA":2292},{"trials":2283,"activeCount":68},[],{"trials":2285,"activeCount":68},[],{"trials":2287,"activeCount":68},[],{"trials":2289,"activeCount":68},[],{"trials":2291,"activeCount":68},[],{"trials":2293,"activeCount":68},[2294],{"nctId":2295,"briefTitle":2296,"status":78,"phases":2297,"primaryCompletion":232,"completion":2298,"start":2299,"enrollment":2300,"conditions":2301,"interventions":2302},"NCT00811421","Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy",[61],"2013-12","2009-09",5820,[2156,2133,18],[2280,2303,2303,2304],"Mefloquine","mefloquine",{"intervention":2303,"totalTrials":95,"cells":2306},{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2308,"activeCount":68},[],{"trials":2310,"activeCount":68},[],{"trials":2312,"activeCount":68},[],{"trials":2314,"activeCount":68},[],{"trials":2316,"activeCount":68},[],{"trials":2318,"activeCount":68},[2319],{"nctId":2295,"briefTitle":2296,"status":78,"phases":2320,"primaryCompletion":232,"completion":2298,"start":2299,"enrollment":2300,"conditions":2321,"interventions":2322},[61],[2156,2133,18],[2280,2303,2303,2304],{"intervention":2324,"totalTrials":95,"cells":2325},"Terlipressin and albumin",{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2327,"activeCount":68},[],{"trials":2329,"activeCount":68},[],{"trials":2331,"activeCount":68},[],{"trials":2333,"activeCount":68},[],{"trials":2335,"activeCount":68},[],{"trials":2337,"activeCount":68},[2338],{"nctId":2339,"briefTitle":2340,"status":78,"phases":2341,"primaryCompletion":2342,"completion":2343,"start":232,"enrollment":2344,"conditions":2345,"interventions":2346},"NCT01932151","Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis",[61],"2013-07","2013-08",18,[252],[2324],{"intervention":2348,"totalTrials":95,"cells":2349},"Antidiabetic treatment by usual care",{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2358,"NA":2360},{"trials":2351,"activeCount":68},[],{"trials":2353,"activeCount":68},[],{"trials":2355,"activeCount":68},[],{"trials":2357,"activeCount":68},[],{"trials":2359,"activeCount":68},[],{"trials":2361,"activeCount":68},[2362],{"nctId":2363,"briefTitle":2364,"status":345,"phases":2365,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":311,"conditions":2368,"interventions":2374},"NCT03594591","Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes",[],"2020-01-01","2018-01-02",[2369,2370,2371,2372,2373],"Type 2 Diabetes Mellitus","Microangiopathy","Diabetic Retinopathy","Arteriosclerosis","Carotid Atherosclerosis",[2348],{"intervention":2376,"totalTrials":95,"cells":2377},"Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2384,"PHASE4":2386,"NA":2388},{"trials":2379,"activeCount":68},[],{"trials":2381,"activeCount":68},[],{"trials":2383,"activeCount":68},[],{"trials":2385,"activeCount":68},[],{"trials":2387,"activeCount":68},[],{"trials":2389,"activeCount":68},[2390],{"nctId":2391,"briefTitle":2392,"status":78,"phases":2393,"primaryCompletion":384,"completion":2394,"start":2395,"enrollment":2396,"conditions":2397,"interventions":2399},"NCT01503489","Risk Factors for AD-Associated Switch to Mania",[],"2011-07","2005-10",221,[2398],"Bipolar Disorder",[2376],{"intervention":2401,"totalTrials":95,"cells":2402},"Testosterone and FSHr-LHr",{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2409,"PHASE4":2411,"NA":2413},{"trials":2404,"activeCount":68},[],{"trials":2406,"activeCount":68},[],{"trials":2408,"activeCount":68},[],{"trials":2410,"activeCount":68},[],{"trials":2412,"activeCount":68},[],{"trials":2414,"activeCount":68},[2415],{"nctId":2416,"briefTitle":2417,"status":345,"phases":2418,"primaryCompletion":2419,"completion":2067,"start":2420,"enrollment":1291,"conditions":2421,"interventions":2423},"NCT01291212","Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone",[61],"2011-06","2011-01",[2422],"Other Complications Associated With Artificial Fertilization",[2401,2424],"testosterone and FSHr alone",{"intervention":2424,"totalTrials":95,"cells":2426},{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2428,"activeCount":68},[],{"trials":2430,"activeCount":68},[],{"trials":2432,"activeCount":68},[],{"trials":2434,"activeCount":68},[],{"trials":2436,"activeCount":68},[],{"trials":2438,"activeCount":68},[2439],{"nctId":2416,"briefTitle":2417,"status":345,"phases":2440,"primaryCompletion":2419,"completion":2067,"start":2420,"enrollment":1291,"conditions":2441,"interventions":2442},[61],[2422],[2401,2424],{"intervention":2444,"totalTrials":95,"cells":2445},"Everolimus Eluting Coronary Stent System",{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2447,"activeCount":68},[],{"trials":2449,"activeCount":68},[],{"trials":2451,"activeCount":68},[],{"trials":2453,"activeCount":68},[],{"trials":2455,"activeCount":68},[],{"trials":2457,"activeCount":68},[2458],{"nctId":2459,"briefTitle":2460,"status":78,"phases":2461,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":2131,"conditions":2464,"interventions":2472},"NCT04462315","10-Years Follow-up of the EXAMINATION Trial",[],"2020-05-31","2015-05-01",[2465,2466,2467,2468,2469,2470,2471],"Myocardial Infarction","ST Elevation Myocardial Infarction","Infarction","Necrosis","Heart Disease","Cardiovascular Diseases","Vascular Diseases",[2444],{"intervention":2115,"totalTrials":95,"cells":2474},{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2476,"activeCount":68},[],{"trials":2478,"activeCount":68},[],{"trials":2480,"activeCount":68},[],{"trials":2482,"activeCount":68},[],{"trials":2484,"activeCount":68},[],{"trials":2486,"activeCount":68},[2487],{"nctId":2108,"briefTitle":2109,"status":78,"phases":2488,"primaryCompletion":2111,"completion":1290,"start":347,"enrollment":500,"conditions":2489,"interventions":2490},[],[2113],[1694,2115],{"intervention":2492,"totalTrials":95,"cells":2493},"switching; dose reduction",{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2500,"PHASE4":2502,"NA":2504},{"trials":2495,"activeCount":68},[],{"trials":2497,"activeCount":68},[],{"trials":2499,"activeCount":68},[],{"trials":2501,"activeCount":68},[],{"trials":2503,"activeCount":68},[],{"trials":2505,"activeCount":68},[2506],{"nctId":2507,"briefTitle":2508,"status":78,"phases":2509,"completion":2510,"start":1087,"enrollment":451,"conditions":2511,"interventions":2513},"NCT00312832","Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy",[61],"2005-02",[18,2512],"Lipoatrophy",[2492],{"intervention":2515,"totalTrials":95,"cells":2516},"administration of autologous bone marrow blood",{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2518,"activeCount":68},[],{"trials":2520,"activeCount":68},[],{"trials":2522,"activeCount":68},[],{"trials":2524,"activeCount":68},[],{"trials":2526,"activeCount":68},[],{"trials":2528,"activeCount":68},[2529],{"nctId":2530,"briefTitle":2531,"status":78,"phases":2532,"primaryCompletion":347,"completion":347,"start":2533,"enrollment":2080,"conditions":2534,"interventions":2536},"NCT00821899","Bone Marrow Autotransplantation in Type 1 Diabetes",[61],"2009-01",[2535],"Type 1 Diabetes Mellitus",[2515]]